Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Departure of a VP
Appointed CFO
Quarterly results
Director comp.
SCOLR Pharma, Inc. (SCLR) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/10/2011 8-K Form 8-K - Current report
07/26/2011 8-K Form 8-K - Current report
05/09/2011 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. First Quarter 2011 Financial Results BOTHELL, WA, May 9, 2011, - SCOLR Pharma, Inc. today reported financial results for the three months ended March 31, 2011 and also provided updates on a number of key corporate objectives. Corporate updates include the following: • The Company amended its lease with the landlord of the Company's principal office in Bothell, Washington. The Company and the landlord agreed to reduce the term of the lease so that it will expire on March 31, 2012 rather than January 31, 2016; to reduce the amount of monthly rent and common area maintenance charges from approximately $38,756 to $11,050; and to forgive all past due amounts for unpaid rent and common area maintenance charges. • Stephen J. Turner, President and Chief Executive Officer, and Ri..."
03/29/2011 8-K Form 8-K - Current report
04/29/2010 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. Reports First Quarter 2010 Financial Results"
03/24/2010 8-K Form 8-K - Current report
08/07/2009 8-K Form 8-K - Current report
05/01/2009 8-K Form 8-K -- Current report
03/11/2009 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results BOTHELL, WA, March 11, 2009, - SCOLR Pharma, Inc. today reported financial results for the three and twelve months ended December 31, 2008. The Company will host a live conference call today, March 11, 2009, at 11:30 a.m. . “Last year was an important period for SCOLR Pharma,” said President and CEO Bruce S. Morra, Ph.D., M.B.A. “Utilizing our unique CDT® platforms, we made significant progress advancing our two primary over-the-counter drug candidates, ibuprofen and pseudoephedrine, through clinical development. During the second half of the year, we reported very positive top-line data from the pivotal Phase III trial of our 12 hour CDT 600 mg controlled release ibuprofen. We are encouraged by the increased interest in our ..."
11/07/2008 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results Pivotal Phase III Trial Primary Endpoints Achieved for SCOLR’s 12-Hour Ibuprofen",
"SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen Pivotal Phase III Trial Primary Endpoints Achieved for SCOLR’s 12 Hour Ibuprofen"
08/07/2008 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results"
05/02/2008 8-K Quarterly results
Docs: ", APRIL 30, 2008 PR",
", MAY 2, 2008 PR"
03/11/2008 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. Reports Year End 2007 Financial Results",
"Presentation materials for the investor presentation by SCOLR Pharma, Inc"
11/02/2007 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. Reports Third Quarter 2007 Financial Results",
"SCOLR Pharma, Inc. Initiates Pivotal Trials for 12-hour Ibuprofen"
08/07/2007 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. Reports Second Quarter 2007 Financial Results"
03/12/2007 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. Reports Year-end 2006 Financial Results"
11/06/2006 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. Reports Third Quarter 2006 Financial Results"
08/07/2006 8-K Quarterly results
Docs: "SCOLR Pharma, Inc. Reports Second Quarter 2006 Financial Results"
05/10/2006 8-K Quarterly results
Docs: "SCOLR Pharma First Quarter 2006 Financial Results"
03/23/2006 8-K Quarterly results
Docs: "SCOLR Pharma Reports Results for 2005 BELLEVUE, WA, March 23, 2006 - SCOLR Pharma, Inc. today reported its financial results for the fiscal year ended December 31, 2005. “We are very pleased with the progress we made in 2005 building a solid foundation for our specialty pharmaceutical business. Our operating results reflect the costs of advancing our business and are consistent with our expectations,” stated Daniel O. Wilds, SCOLR Pharma's President and CEO. “We made significant progress in 2005 executing our strategy of building corporate relationships and successfully testing several of our differentiated CDT® based drug formulations. These development programs are related to drugs with current total U.S. annual sales exceeding $4 billion. In 2006, we intend to evaluate additional dr..."
08/15/2005 8-K Quarterly results
Docs: "SCOLR Pharma Reports Second Quarter and Six-Month Results"
05/12/2005 8-K Quarterly results
Docs: "SCOLR PHARMA REPORTS FIRST QUARTER RESULTS FOR THE PERIOD ENDED MARCH 31, 2005"
08/13/2004 8-K Quarterly results
Docs: "NEWS"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy